SRRK Scholar Rock Holding Corporation
USHealthcareAs of 2026-07-10 16:00
Why SRRK matters now
Scholar Rock Holding Corporation (SRRK) is a US stock in Healthcare. The latest InvestLog snapshot shows $56.71 with -2.12% on the session and $6.80B in market capitalization; recent performance reads 1-month -0.48% and YTD +7.45%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-105.5M, and EPS of $-0.83. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5.4%.
The latest indexable market news headline is "Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $59.00; recent insider activity includes AKKARAJU SRINIVAS filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
21.83
P/S
0.00
EV/EBITDA
-13.63
DCF Value
$1.79
FCF Yield
-5.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-163.5%
ROA
-76.4%
ROIC
-85.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-105.5M | $-0.83 |
| Q4 2025 | $0.00 | $-91.0M | $-0.74 |
| FY 2025 | $0.00 | $-377.9M | $-3.29 |
| Q3 2025 | $0.00 | $-102.2M | $-0.90 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$59.17
Target (Median)
$59.00
Target Range
$55.00 - $65.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.69
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.